Botanix Pharmaceuticals Ltd
ASX:BOT
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.14
0.435
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Botanix Pharmaceuticals Ltd
Botanix Pharmaceuticals Ltd
Total Liabilities & Equity
Botanix Pharmaceuticals Ltd
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
Total Liabilities & Equity
AU$112.5m
|
CAGR 3-Years
72%
|
CAGR 5-Years
85%
|
CAGR 10-Years
46%
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Total Liabilities & Equity
AU$1.1B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Total Liabilities & Equity
AU$228.2m
|
CAGR 3-Years
129%
|
CAGR 5-Years
66%
|
CAGR 10-Years
25%
|
|
|
Probiotec Ltd
ASX:PBP
|
Total Liabilities & Equity
AU$231.4m
|
CAGR 3-Years
10%
|
CAGR 5-Years
15%
|
CAGR 10-Years
8%
|
|
|
Vita Life Sciences Ltd
ASX:VLS
|
Total Liabilities & Equity
AU$68m
|
CAGR 3-Years
19%
|
CAGR 5-Years
15%
|
CAGR 10-Years
11%
|
|
|
Arovella Therapeutics Ltd
ASX:ALA
|
Total Liabilities & Equity
AU$13.3m
|
CAGR 3-Years
8%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
Botanix Pharmaceuticals Ltd
Glance View
Botanix Pharmaceuticals Ltd. engages in the development of therapeutics for the treatment of skin diseases. The company is headquartered in Perth, Western Australia. The firm's product pipelines are based on drug delivery technology known as Permetrex. Its product pipeline consists of three clinical programs, which are using synthetic cannabidiol in the topical treatment of serious skin diseases and for antimicrobial applications. Its product pipeline includes BTX 1503 Gel, BTX 1702 Solution and BTX 1801 Ointment. Its BTX1503 Gel is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. Its BTX 1702 Solution is used for the treatment of papulopustular rosacea. Its BTX 1801 Ointment is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus (MRSA). The firm also has a chemistry program to identify, synthesize and test chemical entities that are related to naturally occurring cannabinoids.
See Also
What is Botanix Pharmaceuticals Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
112.5m
AUD
Based on the financial report for Jun 30, 2024, Botanix Pharmaceuticals Ltd's Total Liabilities & Equity amounts to 112.5m AUD.
What is Botanix Pharmaceuticals Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
46%
Over the last year, the Total Liabilities & Equity growth was 353%. The average annual Total Liabilities & Equity growth rates for Botanix Pharmaceuticals Ltd have been 72% over the past three years , 85% over the past five years , and 46% over the past ten years .
You don't have any saved screeners yet
